SHA, a global health and wellness clinic with locations in Spain and Mexico and plans to expand into the UAE, has spent more than two decades developing a model built around structured, science-based health optimization. Known for its destination-style programs, the brand combines preventative diagnostics, lifestyle interventions and advanced longevity therapies into a single system.
That approach was the focus of a recent panel, where SHA co-founder Alejandro Bataller joined members of the company’s Scientific Advisory Board, including women’s health expert Dr. Jessica Shepherd and stem cell scientist Christian Drapeau, to discuss how the next phase of longevity is taking shape.
The conversation reflected a broader inflection point for the category. While consumer-facing trends point to many proclaimed single-solution therapies, SHA is betting on a more complex, systems-driven model that treats healthspan as something that must be continuously measured and tracked over time.
“There isn’t a magic pill,” Bataller noted. “The foundation is lifestyle optimization, supported by proactive screening and the right scientific protocols to stay ahead.”
The way in which SHA approaches individual goals underscores this strategy. When clients come into their consultations with goals like weight loss or improved energy, their solution is rarely driven by a single factor. SHA, instead, assesses a variety of potential contributing factors to find the root cause of client issues. Underlying drivers can range from hormonal imbalances and chronic stress to inflammation and nervous system dysregulation, reinforcing the need for a more personalized approach to care.
Drapeau argued that part of this care evolution requires rethinking how evidence is interpreted, particularly in emerging fields like regenerative medicine.
“There are things that don’t yet have large-scale studies behind them, but they are very effective,” he said. “We need to take a step back and look at what is actually working in real life.”
He pointed to traditional research models, which tend to isolate variables rather than reflect how the body actually functions. This approach, he noted, was unrealistic when solving for complex health issues.
“In regenerative medicine, you never do one thing,” Drapeau said. “You’re working with a combination, and that combination is different for everybody.”
That perspective demonstrates SHA’s shift toward adaptive, individualized systems where therapies are layered and adjusted based on response.
“That’s where the future is going,” he added. “It becomes really personalized medicine.”
Women’s health is one of the areas where that shift is already underway. Dr. Shepherd highlighted how historically limited research has created gaps in understanding how women age, particularly beyond reproductive health.
“For a long time, there wasn’t a lot of research devoted to women and how their physiology works,” she said. “Women live longer than men, but we live longer lives in poorer health.”
Dr. Sheperd pointed to hormonal decline, particularly in midlife, as a key factor driving that imbalance.
“We never want to wait until the gas tank is empty,” Shepherd said. “We want to support the body when levels start to decline, before it impacts how the body functions.”
That same preventative lens is being applied to cognitive health, an area that panelists described as significantly under-measured relative to its importance. Despite widespread adoption of wearables that track sleep, heart rate and recovery, few individuals have a baseline understanding of their brain function.
Advances in neurotechnology are beginning to shift that understanding, making it possible to measure brain activity more directly through brainwave tracking and other biomarkers. For women, that timeline intersects directly with hormonal changes. Declining estrogen levels have been linked to increased inflammation and changes in brain function, further reinforcing the need for earlier intervention.
Regenerative medicine, including stem cell therapies, was positioned as one of the most promising and still-developing areas within longevity. Unlike traditional treatments that focus on managing symptoms, regenerative approaches aim to restore the body’s underlying ability to repair itself.
Drapeau described this as a fundamental shift in how medicine is practiced.
“Most of what we do today is manage conditions,” he said. “Regenerative medicine is about repairing and giving the body back its normal function.”
At the center of that approach is the body’s endogenous repair system, driven by stem cells. As individuals age, that system becomes less effective, contributing to the development of chronic disease.
“The body has an innate ability to repair,” Drapeau said. “The question is how we leverage that ability as it declines.”
That decline is closely tied to chronic inflammation, which panelists described as one of the primary drivers of aging. Lifestyle factors including diet, sleep, stress and environmental exposure all contribute, often long before symptoms appear. SHA focuses on addressing those inputs early, rather than reacting later.
Bataller emphasized that this is where the concept of longevity as a system becomes most important.
“We’re seeing a lot of isolated treatments being marketed as longevity,” he said. “But longevity is about integrating everything into one system.”
